• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Tome Bio founders wran­gle ‘jump­ing genes’ to cre­ate new pro­gram­ma­ble gene in­ser­tion tool

Last month
R&D

Ira Mell­man joins PI­CI; Vi­iV Health­care CMO re­places Chris Cor­si­co at GSK

Last month
Peer Review

FDA qui­et­ly be­gins re­vers­ing re­turn-to-of­fice man­date for some work­ers

Last month
FDA+

No­var­tis fol­lows Lil­ly and J&J in an­nounc­ing multi­bil­lion-dol­lar US man­u­fac­tur­ing in­vest­ment

Last month
Pharma
Manufacturing

Vac­cines, obe­si­ty drugs, job cuts: Take­aways from RFK Jr.'s first net­work in­ter­view as HHS chief

Last month
People
Pharma

Phar­ma tar­iffs: Here’s what a po­ten­tial roll­out could look like

Last month
Pharma
Manufacturing

The most im­por­tant men­tal health com­pa­ny in 2040

Last month
Health Tech

DHL pours €2B in­to health­care lo­gis­tics; OXB rev­enues on the rise

Last month
Manufacturing

J&J, ar­genx keep rolling out myas­the­nia gravis da­ta, plus more from #AAN25

Last month
R&D

Alzheon’s amy­loid-tar­get­ing pill fails an­oth­er Phase 3 study in Alzheimer’s

Last month
R&D

Biotech CEOs to Cas­sidy: We're al­ready see­ing the ef­fects of FDA's staff cuts

Last month
Pharma
FDA+

Ther­a­py AI chat­bot shows promis­ing re­sults: study

Last month
AI
Health Tech

Tem­pest seeks strate­gic al­ter­na­tives to fund Phase 3 liv­er can­cer tri­al

Last month
Deals

Ex­clu­sive: Car­diometa­bol­ic biotech gets $57.5M Se­ries B, with help from Cy­to­ki­net­ics

Last month
Financing
Startups

Fir­ings of HH­S' pro­ba­tion­ary work­ers can pro­ceed, ap­peals court says

Last month
FDA+
Law

Drug pric­ing watch­dog ICER of­fers ways to in­crease obe­si­ty drug ac­cess

Last month
Pharma
FDA+

Mar­ket tur­moil is tank­ing biotech M&A and IPOs. Here's the play­book star­tups will use to sur­vive

Last month
Financing
Startups

Idor­sia’s blood pres­sure pill no longer re­quires a REMS; Solu rais­es $41M

Last month
News Briefing

No­vo Nordisk looks to Brazil to boost GLP-1 man­u­fac­tur­ing with $1B+ bud­get

Last month
Pharma
Manufacturing

Up­dat­ed: Phar­ma is next in line as Trump says tar­iffs are com­ing 'very short­ly'

Last month
Pharma
Manufacturing

Phar­ma CEOs warn EU of po­ten­tial ‘ex­o­dus to the US’ as trade war con­tin­ues

Last month
Pharma
Manufacturing

House pan­el mulls ways to boost strug­gling US biosim­i­lar mar­ket

Last month
FDA+
Law

NIH ap­peals na­tion­wide block on pay­ment cap for re­search grantees

Last month
Pharma
Law

What stock mar­ket chaos means for health tech

Last month
Health Tech
First page Previous page 15161718192021 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times